Mundipharma International Corporation Limited, Mundipharma Medical Company, and Acrotech Biopharma Inc. Enter Agreement to Transfer License of FOLOTYN® (Pralatrexate) in China to CASI Pharmaceuticals

On August 1, 2023 CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, reported the execution of an Assignment Agreement (the "Agreement") with Mundipharma International Corporation Limited ("MICL"), Mundipharma Medical Company ("MMCo"), and Acrotech Biopharma Inc. ("Acrotech") for the commercialization of FOLOTYN (Pralatrexate) in the People’s Republic of China ("China") (Press release, CASI Pharmaceuticals, AUG 1, 2023, View Source [SID1234640200]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

FOLOTYN (Pralatrexate) is a dihydrofolate reductase inhibitor indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma ("PTCL"). This product was approved by both the US Food and Drug Administration ("FDA") and China’s National Medical Products Administration (NMPA) for PTCL. Under the terms of the Agreement, CASI will assume MICL’s rights and obligations with respect to the commercialization of FOLOTYN in China.

Wei-Wu He, Ph.D., CASI’s Chairman and Chief Executive Officer, commented, "We are very pleased to add FOLOTYN, another unique and approved drug product to our commercial portfolio. The licensing of FOLOTYN is consistent with the company’s strategy to grow our hematological malignancy therapeutic area franchise. We will leverage CASI’s existing sales and commercial team’s established capabilities and infrastructure to launch and commercialize FOLOTYN."

"CASI has proven and strong capability to commercialize proprietary medications and are extremely pleased to broaden our existing relationship with them. We look forward to this exciting launch and bringing this novel medicine to PTCL patients in China," said Dr. Ashish Anvekar, President of Acrotech Biopharma.